Drug Profile


Alternative Names: PST 2238

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Developer CVie Therapeutics; Rostaquo; sigma-tau SpA
  • Class Androstanes; Antihypertensives; Furans; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertension

Most Recent Events

  • 18 Dec 2015 Phase-II clinical trials in Hypertension in Taiwan (PO) (CVT-CV-001)
  • 03 Aug 2015 Taiwan's Ministry of Health and Welfare approves an application to conduct a phase IIb study for Hypertension in Taiwan
  • 12 Jun 2013 CVie Therapeutics initiates enrolment in a phase IIb trial for Hypertension in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top